Report cover image

Gallbladder Cancer - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 50 Pages
SKU # DEL19995170

Description

DelveInsight’s, “Gallbladder cancer - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gallbladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Gallbladder cancer Understanding

Gallbladder cancer: Overview

Gallbladder cancer is a small, pear shaped organ located beneath the liver. The bladder stores bile enzymes produced by the liver and helps in digestion. Gallbladder cancer is a rare type of cancer that is characterized by the abnormal growth of cells in the Gallbladder cancer area. Most of the Gallbladder cancer begins in glandular cells which form the lining of the inner surface of the organ. This type of cancer is very rare and is caused due to the DNA mutations in the Gallbladder cancer cells. Gallbladder cancer is more common in middle aged women with a history of gallstones. However, it can also occur in men. Gallbladder cancer can be of various types such as papillary adenocarcinomas, adenosquamous carcinoma, squamous cell carcinoma, and others.

""Gallbladder cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder cancer pipeline landscape is provided which includes the disease overview and Gallbladder cancer treatment guidelines. The assessment part of the report embraces, in depth Gallbladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.
Gallbladder cancer Emerging Drugs Chapters

This segment of the Gallbladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gallbladder cancer Emerging Drugs
  • Durvalumab: Celgne
Celgene’ new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.
  • ONC 201: Ohara Pharmaceuticals
Ohara Pharmaceutical’s “breakthrough” drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.

Further product details are provided in the report……..

Gallbladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gallbladder cancer drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Gallbladder cancer
There are approx. 10+ key companies which are developing the therapies for Gallbladder cancer. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Gallbladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intramuscular
  • Intravenous
  • Subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gallbladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gallbladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder cancer drugs.

Gallbladder cancer Report Insights
  • Gallbladder cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Gallbladder cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Gallbladder cancer drugs?
  • How many Gallbladder cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gallbladder cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gallbladder cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gallbladder cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Celgene
  • MedImmune
  • Ohara Pharmaceuticals
Key Products
  • Durvalumab
  • Tremelimumab
  • ONC 201

Table of Contents

50 Pages
Introduction
Executive Summary
Gallbladder cancer: Overview
● Causes
● Mechanism of Action
● Signs and Symptoms
● Diagnosis
● Disease Management
Pipeline Therapeutics
● Comparative Analysis
Therapeutic Assessment
● Assessment by Product Type
● Assessment by Stage and Product Type
● Assessment by Route of Administration
● Assessment by Stage and Route of Administration
● Assessment by Molecule Type
● Assessment by Stage and Molecule Type
Gallbladder cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
● Gallbladder cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gallbladder cancer Collaboration Deals
● Company-Company Collaborations (Licensing / Partnering) Analysis
● Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
● Comparative Analysis
Durvalumab : Celgene
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
● Comparative Analysis
ONC 201: Ohara Pharmaceuticals
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
● Comparative Analysis
Gallbladder cancer Key Companies
Gallbladder cancer Key Products
Gallbladder cancer- Unmet Needs
Gallbladder cancer- Market Drivers and Barriers
Gallbladder cancer- Future Perspectives and Conclusion
Gallbladder cancer Analyst Views
Gallbladder cancer Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us